MedTrace Logo

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

NCT00115076 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2021-02-08

Study results available
· View outcomes & findings →

Summary

Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Efalizumab, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The eligible patient will have 10% of his/her body surface area involved with psoriasis vulgaris.

Conditions

Interventions

DRUG

Efalizumab

24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Rockefeller University

    lead OTHER

Principal Investigators

  • James Krueger, MD · Rockefeller University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-04
Primary Completion
2009-05-18
Completion
2011-04-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00115076 on ClinicalTrials.gov